What is Novavax's change in AP?

Novavax (NVAX) reported change in AP of -$60.08M in Q1 2026.

How has Novavax's change in AP changed year-over-year?

Novavax's change in AP increased by 71.6% year-over-year, from -$211.85M to -$60.08M.

What is the long-term trend for Novavax's change in AP?

Over 3 years (2021 to 2025), Novavax's change in AP has grown at a -18.7% compound annual growth rate (CAGR), from $600.33M to -$322.57M.

What does change in AP mean?

Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.

Novavax NVAX Change in AP

Change in AP at other companies

ModernaMRNA

-$120M+23.1%

Roivant SciencesROIV

$16.16M+9,891%

Merck & Co.MRK

$27.5M-39.6%

Vaxcyte, Inc.PCVX

-$269K+99.1%

Viridian Therapeutics, Inc.VRDN

$4.63M+162%

ALN

Alnylam PharmaceuticalsALNY

-$176.03M-11.6%

Other financials

Income statement

See full

Revenue$139.5M-79.1%

Gross profit$108.8M-83.3%

Operating income-$15.4M-103%

Net income-$9.5M-102%

EPS (diluted)-$0.06-102%

Balance sheet

See full

Cash & equivalents$228.4M-13.3%

Total debt$295.1M+404%

Total equity-$144.8M-91.4%

Total assets$1.0B-19.3%

Cash flow

See full

Operating cash flow-$32.4M+82.5%

CapEx$1.3M-20.4%

Free cash flow-$33.7M+82.0%

Valuation

See full

Market cap$1.46B+35.6%

Enterprise value$1.53B+76.9%

P/S2.5×+1.6×

Profitability

See full

Gross margin85%-2.5pp

Operating margin-13.1%-45.9pp

Net margin-14.7%-52.9pp

FCF margin-58.9%-61.4pp

Returns & leverage

See full

Return on equity-238.6%—

Debt / equity1.5×—

Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Novavax's change in AP?: Novavax (NVAX) reported change in AP of -$60.08M in Q1 2026.
How has Novavax's change in AP changed year-over-year?: Novavax's change in AP increased by 71.6% year-over-year, from -$211.85M to -$60.08M.
What is the long-term trend for Novavax's change in AP?: Over 3 years (2021 to 2025), Novavax's change in AP has grown at a -18.7% compound annual growth rate (CAGR), from $600.33M to -$322.57M.
What does change in AP mean?: Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.